Literature DB >> 12703833

High-dose midazolam and the attenuation of the contractile response to vasoconstrictors in coronary artery segments.

A P Klockgether-Radke1, A Thudium, A Frerichs, D Kettler, G Hellige.   

Abstract

BACKGROUND AND
OBJECTIVE: Benzodiazepines may cause hypotension and are reported to interfere with smooth vascular muscle activity. The aim was to elucidate the influence of three different benzodiazepines on the vascular reactivity of coronary arteries.
METHODS: Using the model of isolated vessels, we studied the impact of midazolam (0.15, 1.5, 15 microg mL(-1)), diazepam (0.1, 1.0, 10 microg mL(-1)) and flunitrazepam (0.01, 0.1, 1.0 microg mL(-1)) on the contractile responses to histamine (2 x 10(-5) mol L(-1)) and serotonin (3 x 10(-5) mol L(-1)) in isolated intact and denuded coronary arteries.
RESULTS: Midazolam significantly attenuated the contractile response when administered in high concentrations (15 microg mL(-1)). This effect was more pronounced in intact than in denuded preparations (histamine: -22.7 versus -7.3%, P = 0.0079; serotonin: -47.1 versus -15.9%, P < 0.0001). Diazepam and flunitrazepam exerted no significant effects on the vascular tone of coronary arteries.
CONCLUSIONS: Midazolam, but not diazepam or flunitrazepam, attenuates the contractile responses to vasoconstrictors in concentrations beyond those used in clinical practice. This effect is in part mediated by endothelial factors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12703833     DOI: 10.1017/s0265021503000450

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  1 in total

1.  Noninvasive assessment of pulse-wave velocity and flow-mediated vasodilation in anesthetized Göttingen minipigs.

Authors:  Trine P Ludvigsen; Niels Wiinberg; Christina J Jensen; Annemette T Callesen; Regitze W Andersen; Anne Sofie H Jørgensen; Berit Ø Christoffersen; Henrik D Pedersen; Sophia G Moesgaard; Lisbeth H Olsen
Journal:  Comp Med       Date:  2014-12       Impact factor: 0.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.